Back to discover
Disease

Hemorrhagic Stroke

Late-stage therapeutic developmentEmerging research
MeSHHemorrhagic Stroke
2
Publications
24
Clinical trials
1
Related conditions
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones8View
Results expected 2
Recently completed 3
Other updates 3
Activity timeline8

Clinical trials

14 sponsors · 3 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)

Phase 3 · Active, not recruiting · Wan-Jin Chen

CHemical OptImization of Cerebral Embolectomy in Patients With Acute Stroke Treated With Mechanical Thrombectomy 2 (CHOICE 2 TRIAL)

Phase 3 · Active, not recruiting · Hospital Clinic of Barcelona

Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial

Phase 3 · Active, not recruiting · Grace Therapeutics Inc.

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)

Phase 3 · Active, not recruiting · Capital Medical University

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S
Recently completed

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily

Phase 3 · Completed · Boehringer Ingelheim

EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study

Phase 4 · Completed · Boehringer Ingelheim

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major themes6
  • Hemorrhagic Stroke2
  • Stroke2
  • Brain Injuries1
  • Brain Ischemia1
  • Brain Neoplasms1
  • Cognitive Dysfunction1
Leading journals2
  • Journal of neuroinflammation1
  • Stroke1
Leading researchers8
  • Aparicio HJ1
  • Blake ML1
  • Byun E1
  • Chen Y1
  • Duan M1
  • El Husseini N1
  • Feng H1
  • Gottesman RF1
Affiliations (unnormalised)3
  • Chongqing Clinical Research Center for Neurosurgery1
  • Chongqing Key Laboratory of Intelligent Diagnosis1
  • State Key Laboratory of Trauma1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Stroke2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Stroke due to rupture of a weakened blood vessel in the brain (e.g., CEREBRAL HEMISPHERES; CEREBELLUM; SUBARACHNOID SPACE).

Identifiers
MeSHHemorrhagic Stroke
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.